2XCR

The 3.5A crystal structure of the catalytic core (B'A' region) of Staphylococcus aureus DNA Gyrase complexed with GSK299423 and DNA

Summary for 2XCR

• Entry DOI: 10.2210/pdb2xcr/pdb
• Related: 2XCO 2XCQ 2XCS 2XCT
• Descriptor: DNA GYRASE SUBUNIT B, DNA GYRASE SUBUNIT A, 5'-D(*5UA*GP*CP*CP*GP*TP*AP*GP*GP*GP*CP*CP*CP*TP*AP*CP*GP *GP*CP*TP)-3', 5'-D(*AP*GP*CP*CP*GP*TP*AP*GP*GP*GP*CP*CP*CP*TP*AP*CP*GP *GP*CP*TP)-3', ... (4 entities in total)
• Functional Keywords: isomerase
• Biological source: STAPHYLOCOCCUS AUREUS; More
• Cellular location: Cytoplasm (Potential): Q99XG5
• Total number of polymer chains: 8
• Total formula weight: 354710.63

Authors

Bax, B.D.,Chan, P.F.,Eggleston, D.S.,Fosberry, A.,Gentry, D.R.,Gorrec, F.,Giordano, I.,Hann, M.M.,Hennessy, A.,Hibbs, M.,Huang, J.,Jones, E.,Jones, J.,Brown, K.K.,Lewis, C.J.,May, E.W.,Singh, O.,Spitzfaden, C.,Shen, C.,Shillings, A.,Theobald, A.F.,Wohlkonig, A.,Pearson, N.D.,Gwynn, M.N. (deposition date: 2010-04-25, release date: 2010-08-04, Last modification date: 2024-05-08)

Primary citation

Bax, B.D.,Chan, P.F.,Eggleston, D.S.,Fosberry, A.,Gentry, D.R.,Gorrec, F.,Giordano, I.,Hann, M.M.,Hennessy, A.,Hibbs, M.,Huang, J.,Jones, E.,Jones, J.,Brown, K.K.,Lewis, C.J.,May, E.W.,Saunders, M.R.,Singh, O.,Spitzfaden, C.,Shen, C.,Shillings, A.,Theobald, A.F.,Wohlkonig, A.,Pearson, N.D.,Gwynn, M.N.
Type Iia Topoisomerase Inhibition by a New Class of Antibacterial Agents.
Nature, 466:935-, 2010

PubMed Abstract: Despite the success of genomics in identifying new essential bacterial genes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multidrug resistance. Type IIA topoisomerases cleave and religate DNA to regulate DNA topology and are a major class of antibacterial and anticancer drug targets, yet there is no well developed structural basis for understanding drug action. Here we report the 2.1 A crystal structure of a potent, new class, broad-spectrum antibacterial agent in complex with Staphylococcus aureus DNA gyrase and DNA, showing a new mode of inhibition that circumvents fluoroquinolone resistance in this clinically important drug target. The inhibitor 'bridges' the DNA and a transient non-catalytic pocket on the two-fold axis at the GyrA dimer interface, and is close to the active sites and fluoroquinolone binding sites. In the inhibitor complex the active site seems poised to cleave the DNA, with a single metal ion observed between the TOPRIM (topoisomerase/primase) domain and the scissile phosphate. This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class.

PubMed: 20686482
DOI: 10.1038/NATURE09197

Experimental method

X-RAY DIFFRACTION (3.5 Å)